We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
105 hedge funds and large institutions have $95.9M invested in Lyell Immunopharma in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
10% more call options, than puts
Call options by funds: $11K | Put options by funds: $10K
0.06% more ownership
Funds ownership: 2.51% → 2.57% (+0.06%)
10% less funds holding
Funds holding: 117 → 105 (-12)
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
46% less capital invested
Capital invested by funds: $177M → $95.9M (-$80.7M)
Holders
105
Holders Change
-12
Holders Change %
-10.26%
% of All Funds
1.38%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
21
Increased
33
Reduced
25
Closed
32
Calls
$11K
Puts
$10K
Net Calls
+$1K
Net Calls Change
-$38K
Top Buyers
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$11.8M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$8.06M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
+$7.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.72M |
| 5 |
Renaissance Technologies
New York
|
+$1.4M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$2.96M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.93M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.65M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1,000K |
| 5 |
HF
HRT Financial
New York
|
-$785K |
